OBJECTIVE: The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior. METHOD: Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA. RESULTS:Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age >or=18 months completed the cognitive part of the study. No decline in performance occurred with risperidone. Performance on a cancellation task (number of correct detections) and a verbal learning task (word recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal improvement also occurred on a spatial memory task. There were no significant differences between treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task (timed math test). CONCLUSION:Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no detrimental effect on cognitive performance.
RCT Entities:
OBJECTIVE: The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior. METHOD: Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA. RESULTS: Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age >or=18 months completed the cognitive part of the study. No decline in performance occurred with risperidone. Performance on a cancellation task (number of correct detections) and a verbal learning task (word recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal improvement also occurred on a spatial memory task. There were no significant differences between treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task (timed math test). CONCLUSION:Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no detrimental effect on cognitive performance.
Authors: Gahan J Pandina; Robert Bilder; Philip D Harvey; Richard S E Keefe; Michael G Aman; Georges Gharabawi Journal: Biol Psychiatry Date: 2007-01-08 Impact factor: 13.382
Authors: Susan R McGurk; Cameron Carter; Robert Goldman; Michael F Green; Stephen R Marder; Haiyi Xie; Nina R Schooler; John M Kane Journal: Am J Psychiatry Date: 2005-05 Impact factor: 18.112
Authors: Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2002-06 Impact factor: 18.112
Authors: Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith Journal: J Can Acad Child Adolesc Psychiatry Date: 2010-05
Authors: Prescott T Leach; Shane G Poplawski; Justin W Kenney; Barbara Hoffman; Dan A Liebermann; Ted Abel; Thomas J Gould Journal: Learn Mem Date: 2012-07-16 Impact factor: 2.460
Authors: Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont Journal: Nat Rev Drug Discov Date: 2017-12-08 Impact factor: 84.694
Authors: Cristan A Farmer; Jeffery N Epstein; Robert L Findling; Kenneth D Gadow; L Eugene Arnold; Heidi Kipp; David J Kolko; Eric Butter; Jayne Schneider; Oscar G Bukstein; Nora K McNamara; Brooke S G Molina; Michael G Aman Journal: J Child Adolesc Psychopharmacol Date: 2016-06-27 Impact factor: 2.576